A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.
about
Rational Combinations of Targeted Agents in AMLTargeting truncated RXRα for cancer therapy.Reduction in promotor methylation utilizing EGCG (epigallocatechin-3-gallate) restores RXRα expression in human colon cancer cells.D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation.
P2860
A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase I dose escalation stud ...... citabine in patients with AML.
@ast
A phase I dose escalation stud ...... citabine in patients with AML.
@en
type
label
A phase I dose escalation stud ...... citabine in patients with AML.
@ast
A phase I dose escalation stud ...... citabine in patients with AML.
@en
prefLabel
A phase I dose escalation stud ...... citabine in patients with AML.
@ast
A phase I dose escalation stud ...... citabine in patients with AML.
@en
P2093
P2860
P356
P1476
A phase I dose escalation stud ...... ecitabine in patients with AML
@en
P2093
Amanda F Cashen
Camille N Abboud
Haixia Niu
Iskra Pusic
John F Dipersio
John S Welch
Keith E Stockerl-Goldstein
Mark A Schroeder
Meagan Jacoby
Peter Westervelt
P2860
P304
P356
10.1002/AJH.23735
P577
2014-04-28T00:00:00Z